USA Insider Trading Pulse — June 23, 2026

CEO Barrocas Mark sold 100,000 shares for $14M at $140.00 under a 10b5-1 plan, representing a ~4% liquidation of his stake. This is the largest single sell by value in the dataset and occurs as the stock has likely appreciated.

CFO Hou Tianyu and COO Ye Gang sold a combined ~$1.28M in shares under 10b5-1 plans at an average price near $90, near the stock's recent high. The CFO sold 100% of his previously reported holdings (now only 20,000 shares).

10% owner AngelList Asset Management bought 93,675 shares for $1.95M at $20.81, increasing its stake by ~23%. This is a strong signal of conviction by a sophisticated institutional investor.

CEO Chan Chun Sing bought 10,000 shares in two open-market transactions at $1.42-$1.43 for ~$14K. This is a small open-market buy by the top executive, often a contrarian signal of undervaluation.

VP Yuan Lipen bought 1,000 shares at $79.19 for $79K, his first significant open-market purchase in the dataset. This insider buy at an important price level is a positive signal for the semiconductor bellwether.

Chief Administration Officer Uang Du-Tsuen sold 11,000 shares across three transactions at prices ranging from $611 to $697, netting over $7.2M. The sales were made at escalating prices, suggesting progressive profit-taking.

Six top executives, including CEO Jensen Huang, had a combined ~$40M in shares withheld for taxes at $207.41. While not a discretionary sale, this removes potential overhang as these shares are cancelled, effectively a net share reduction.

Two directors, Boris Epshteyn and David Bernhardt, were awarded a combined 70,800 shares, representing a significant equity grant. This aligns board interests with shareholders but also creates future selling pressure.

CEO Mark Barrocas sold $14M in a single transaction under a 10b5-1 plan. While pre-planned, the sheer size signals the CEO is monetizing a large position, which could be a red flag if the stock faces headwinds from slowing demand.

CFO Hou Tianyu's holdings dropped to a minimal 20,000 shares after selling nearly all his stake. This near-complete liquidation by the top financial officer is a strong risk signal for a company still working towards sustained profitability.

The CAO sold shares in three tranches at increasing prices from $611 to $697, suggesting a deliberate plan to exit a large position. If top insiders are taking profits at these levels, it may indicate perceived near-term value ceiling for the stock.

President and COO McNeill Jonathan sold 20,549 shares at $17.99 for $370K under a 10b5-1 plan. Insider sales at a biotech company, especially after recent drug news, can signal a lack of confidence in upcoming catalysts.

Director HASSAN EMIL E sold 5,937 shares for $1.19M at $200. This is a large, direct open-market sale by a director, not a 10b5-1 plan, which carries more weight as a discretionary bearish signal.

Director HOWARD JULIE sold 10,585 shares at $0.13 for a paltry $1.42K. While a small amount, selling shares at a near-penny stock price is a bearish signal of minimal confidence in any recovery.

Director Callinicos Brent was awarded 2,336 shares. This adds to the dilutive overhang at a company already facing retail headwinds, potentially pressuring EPS growth.

With ~$40M in shares withheld for taxes at $207.41, the net reduction in shares outstanding (since these are cancelled) provides a small but steady buyback effect, supporting EPS growth for long-term holders.

The $2M open-market purchase by a 10% owner is a clear vote of confidence. For a venture capital access fund, such insider buying suggests management believes the NAV is undervalued relative to the market.

The VP's $79K open-market purchase is a high-conviction signal from an executive who is typically not a buyer. This aligns with a bullish view on the AI semiconductor cycle.

The CEO's small open-market buys at $1.42 could be a signal that the stock is undervalued. For micro-cap investors, this is a catalyst to investigate the company's fundamentals.

If the CEO's 10b5-1 plan is now complete, the stock may shed the overhang. Watch for insider buying or a stabilization in price as a contrarian entry point.

The CEO and top executives were awarded substantial RSUs (e.g., CEO Gupta got up to 217 RSUs). This links compensation to long-term stock performance, aligning with shareholder interests.

CEO Avellan entered a forward contract to sell 2.5M shares pledged as collateral. This could be a liquidity management tool rather than a pure bearish signal; monitoring the outcome could reveal value if the stock performs.

Both Sea Ltd and ASE Technology insiders sold large positions at or near 52-week highs. This suggests a common theme of tech sector executives taking profits amidst valuation expansion, a contrarian indicator for the sector. Aggregate insider selling in US-listed Asian tech firms appears elevated.

12 of 50 filings were from Enact Holdings, all involving restricted stock or deferred stock awards. While non-directional, this volume of equity grants creates future selling pressure and dilutes current holders, a pattern common in insurance and financial services.

NVIDIA saw pure tax-withholding (neutral/positive supply effect), while TSM saw a rare open-market buy. This split suggests differing insider sentiment within the AI semiconductor ecosystem: NVDA executives are passive, while one TSM insider is actively bullish.

Click Holdings CEO buying small amounts in the open market is a classic micro-cap bullish signal. In the absence of institutional coverage, insider buys are the most reliable signal for these names.

Both Crescent Biopharma and Vertex saw insider sales under 10b5-1 plans. This is a common pattern in biotech, where executives sell to diversify after positive trial results, but it can also precede share price weakness.

Monitor if CFO and COO continue to sell in coming weeks. If the 10b5-1 plan has remaining trades, further liquidations could pressure the stock. Next earnings call is a key catalyst.

Watch for updates on the CEO's forward contract and the status of shares pledged as collateral. Any margin call or accelerated sale could disrupt the stock.

Following the CEO's $14M sale, monitor for any insider buying or share repurchase announcements. A lack of buyback support post-sale would be a negative signal.

Track further 10% owner purchases. If the buying pattern continues, it could indicate a re-valuation catalyst for the fund.

With Q2 close in July, watch for insider purchases if the stock corrects. The current pattern is all tax-withholding, which is supportive.

Directors' awards create new shares. Monitor for any insider sales post-vesting, especially if the stock price approaches recent highs.

Multiple executives had shares withheld for taxes at $0.02. This near-zero price suggests severe financial distress; watch for BK risk or reverse split announcements.